AngioDynamics Partners with Microsulis

AngioDynamics has established a “strategic relationship” with Microsulis Medical in Denmead, England according to press releases from both companies.

AngioDynamics has invested $5 million in Microsulis, establishing 14.3 percent ownership. The companies share common interests: AngioDynamics provides minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, while Microsulis specializes in minimally invasive, microwave ablation technology for the coagulation of soft tissue. Moreover, Microsulis has a presence in more than 80 hospitals globally, according to the company.

Microsulis has minimal representation in the United States, with five sales representative for all 50 states. Its partnership with AngioDynamics will expand its reach in North America. On the other hand, AngioDynamics will benefit from Microsulis’ broader presence in Europe. AngioDynamics has been granted exclusive distribution rights to market and sell the Accu2i pMTA microwave ablation system in all markets outside the United States from May 2012 through December 2013. The company also has the exclusive option to purchase substantially all of the global assets of Microsulis, including the microwave ablation technology and its worldwide distribution rights until Sept. 22 this year..

The Accu2i pMTA microwave ablation system is Microsulis’ flagship product. The system is intended for percutaneous use, which means accessing internal organs with the use of a needle rather than cutting with, for instance, a scalpel. This particular system utilizes a single, high power, high frequency needle that is saline-cooled and was cleared by the U.S. Food and Drug Administration in August 2010.

Albany, N.Y.-based AngioDynamics is expecting to see a “modest” revenue influx from this partnership in fiscal year 2012, according to President and CEO Joe DeVivo.